Alto Neuroscience, Inc.
ANRODrugs in Pipeline
29
Phase 3 Programs
7
Upcoming Catalysts
9
Next Catalyst
May 30, 2026
16dMarket Overview
Stock performance and key metrics
9 upcoming, 2 past
HS628+MTX
Moderate to Severe Active Rheumatoid Arthritis
Apatinib
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
tirapazamine
HCC
STI-1558
COVID-19
HS-25
Primary Hypercholesterolemia
LM-302
Malignant Neoplasms of Digestive Organs
HS022
HER2-positive Breast Cancer
VB15010
Cancer
JX11502MA
Schizophrenia
GB001 recombinant peptide spray low dose group、high dose group
Healthy
ALTO-100
Bipolar Disorder I or II With a Major Depressive Episode
ALTO-300 oral (PO) tablet
Major Depressive Disorder
ALTO-100 PO tablet
Major Depressive Disorder
ALTO-300 PO Tablet
Major Depressive Disorder
ALTO-300
Major Depressive Disorder
ALTO-203 25 μg
Major Depressive Disorder
ALTO-101
Schizophrenia
PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days
Bronchial Asthma
PA1010
Chronic HBV Infection
PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days
Bronchial Asthma
PA9159 nasal spray solution, 10 μg once daily for 14 days
Allergic Rhinitis
DR30206
Gastrointestinal Cancer
ALTO-207
Treatment-resistant Depression (TRD)
LM-302 Injection
Advanced Solid Tumor
HS006+CHOP
Diffuse Large B-cell Lymphoma
Hypidone Hydrochloride tablets
Major Depressive Disorder
AST-3424
HCC - Hepatocellular Carcinoma
DR10624 Injection
MASLD
STI-6129
Relapsed or Refractory Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HS628+MTX | Phase 3 | Moderate to Severe Active Rheumatoid Arthritis | - | - |
Apatinib | Phase 3 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | - | - |
tirapazamine | Phase 3 | HCC | - | - |
STI-1558 | Phase 3 | COVID-19 | - | - |
HS-25 | Phase 3 | Primary Hypercholesterolemia | - | - |
LM-302 | Phase 3 | Malignant Neoplasms of Digestive Organs | - | - |
HS022 | Phase 3 | HER2-positive Breast Cancer | - | - |
VB15010 | Phase 2 | Cancer | - | - |
JX11502MA | Phase 2 | Schizophrenia | - | - |
GB001 recombinant peptide spray low dose group、high dose group | Phase 2 | Healthy | - | - |
ALTO-100 | Phase 2 | Bipolar Disorder I or II With a Major Depressive Episode | - | - |
ALTO-300 oral (PO) tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-100 PO tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-300 PO Tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-300 | Phase 2 | Major Depressive Disorder | - | - |
ALTO-203 25 μg | Phase 2 | Major Depressive Disorder | - | - |
ALTO-101 | Phase 2 | Schizophrenia | - | - |
PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days | Phase 2 | Bronchial Asthma | - | - |
PA1010 | Phase 2 | Chronic HBV Infection | - | - |
PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days | Phase 2 | Bronchial Asthma | - | - |
PA9159 nasal spray solution, 10 μg once daily for 14 days | Phase 2 | Allergic Rhinitis | - | - |
DR30206 | Phase 2 | Gastrointestinal Cancer | - | - |
ALTO-207 | Phase 2 | Treatment-resistant Depression (TRD) | - | - |
LM-302 Injection | Phase 2 | Advanced Solid Tumor | - | - |
HS006+CHOP | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
Hypidone Hydrochloride tablets | Phase 2 | Major Depressive Disorder | - | - |
AST-3424 | Phase 2 | HCC - Hepatocellular Carcinoma | - | - |
DR10624 Injection | Phase 2 | MASLD | - | - |
STI-6129 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
Diffuse Large B-cell Lymphoma
1 drug in this indication
Major Depressive Disorder
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Gastrointestinal Cancer
1 drug in this indication
HCC - Hepatocellular Carcinoma
1 drug in this indication
HER2-positive Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)